Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA

OBJECTIVES: Evaluating the cost-effectiveness of pembrolizumab plus standard chemotherapy in the first-line setting for patients with metastatic non-small cell lung cancer (NSCLC) from the US payer perspective. DESIGN: A Markov model was constructed to analyse the cost-effectiveness of pembrolizumab...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMJ Open
Main Authors: Zeng, Xiaohui, Wan, Xiaomin, Peng, Liubao, Peng, Ye, Ma, Fang, Liu, Qiao, Tan, Chongqing
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2019
Assuntos:
Health Economics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6924863/
https://ncbi.nlm.nih.gov/pubmed/31831534
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2019-031019
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados